PathAI, founded by Andrew Beck, applies AI to digital pathology, analyzing tissue slide images to assist pathologists in diagnosing disease, with its AISight Dx platform aimed at making pathology diagnosis faster and more consistent across labs and hospital systems.
The company reached a genuine regulatory milestone when AISight Dx received FDA 510(k) clearance for primary diagnosis in clinical settings in June 2025, building on an earlier 2022 clearance, and the FDA clearance included a Predetermined Change Control Plan letting PathAI validate future updates without new submissions each time. In February 2026, Labcorp expanded its collaboration with PathAI to deploy AISight Dx across its national network of pathology labs.
Enterprise pricing is quote-based around lab volume and deployment scope, requiring a direct sales conversation rather than published self-serve rates. For a pathology lab or hospital system that wants an FDA-cleared AI platform for primary diagnosis deployed at national scale, PathAI's AISight Dx addresses that directly.
